Momenta Pharmaceuticals (NASDAQ:MNTA) is up 5.1% after hours, building on day’s gains of 23.7% after JPMorgan raised its rating to Overweight.
After the company put out its 2020 outlook, analyst Eric Joseph pointed out that results from the phase 1/2 study of M254 in idiopathic thrombocytopenic purpura were compelling, with relative potency compared to a more conventional IVIg approach.
He’s increased his year-end target to $30 from $14, now implying 18% upside.
Sell-side analysts are Bullish overall, while the stock has a Quant Rating of Neutral.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.